Neurogene (NGNE) Equity Ratio (2018 - 2025)
Neurogene's Equity Ratio history spans 6 years, with the latest figure at 0.92 for Q4 2025.
- For Q4 2025, Equity Ratio fell 0.72% year-over-year to 0.92; the TTM value through Dec 2025 reached 0.92, down 0.72%, while the annual FY2025 figure was 0.92, 0.72% down from the prior year.
- Equity Ratio reached 0.92 in Q4 2025 per NGNE's latest filing, down from 0.92 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.93 in Q1 2025 to a low of 2.05 in Q3 2023.
- Average Equity Ratio over 3 years is 0.21, with a median of 0.87 recorded in 2024.
- Peak YoY movement for Equity Ratio: soared 154.62% in 2024, then fell 0.72% in 2025.
- A 3-year view of Equity Ratio shows it stood at 0.84 in 2023, then increased by 10.61% to 0.92 in 2024, then dropped by 0.72% to 0.92 in 2025.
- Per Business Quant, the three most recent readings for NGNE's Equity Ratio are 0.92 (Q4 2025), 0.92 (Q3 2025), and 0.92 (Q2 2025).